RxDoctor Payments Data

Ali Mehdi, MD

Nephrology · Cleveland, OHNPI 1104108570

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $58,514 of the $75,686 with a category attached, or 77.3%. 14 manufacturers reported payments, led by AstraZeneca at 37.5% of the total. Among nephrology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,686in general payments, 2019–2025

Across 67 payments — averaging $1129.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$28K
  • Novartis$27K
  • GSK$11K
  • Apellis Pharmaceuticals, Inc.$6K
  • Calliditas Therapeutics US Inc.$3K
  • Amgen$156
  • plus $408 from 8 others

What the payments were for

  • Consulting fees$58,51477%
  • Speaking & faculty fees$11,13015%
  • Travel & lodging$3,7405%
  • Food & beverage$2,1953%
  • Education$1080%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,686 in reported general payments places this provider in the 95th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$43,916
Medicare patients
209
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate24$19,924
FarxigaDapagliflozin Propanediol13$18,746
JardianceEmpagliflozin11$16,168
Losartan Potassium86$936
Torsemide48$519
Spironolactone38$437
Amlodipine Besylate78$363
Carvedilol38$240
Metoprolol Succinate15$182
Lisinopril18$121
Hydralazine Hcl17$116
Allopurinol17$115
Atorvastatin Calcium20$105
Furosemide22$75
Hydrochlorothiazide13$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$28,346$38,67037 claims
Boehringer IngelheimJardiance$26$16,16811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 nephrology providers in Ohio.

Other nephrology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →